ADIA Nutrition Inc. (ADIA) reports developments tied to its regenerative medicine, stem cell therapy, and biologic products business. The company operates through Adia Med clinics, which offer treatments such as PRP, AHSCT, orthopedic care, pain management, and wound repair, and through Adia Labs, which develops and sells biologic products including AdiaVita and AdiaLink.
Company news commonly covers clinical and regulatory activity involving AdiaVita, including study programs in chronic kidney disease, autism spectrum disorder, and chronic lower back pain. Updates also address operating results, product sales and medical-service revenue, capital-structure disclosures, governance matters, and the company's transition from a supplement-oriented business toward regenerative healthcare.
Adia Nutrition Inc. (OTCQB: ADIA) has achieved a significant milestone with its medical subsidiary, Adia Med, securing approval as an in-network provider for Aetna health insurance effective July 25, 2025. The partnership grants access to 39 million Aetna members and a network of 1.8 million health professionals.
The company is also on track for approval with United Healthcare, the nation's largest health insurer with 15% market share, expected by August 1, 2025. These partnerships will enable broader access to Adia Med's regenerative therapies, including Autologous Hematopoietic Stem Cell Transplantation (AHSCT), Therapeutic Plasma Exchange (TPE), and Medical Nutrition Therapy (MNT).
Adia Nutrition Inc. (OTCQB: ADIA) has announced that its medical subsidiary, Adia Med, has filed to become an in-network provider with TRICARE, a healthcare program serving 9.5 million military-related beneficiaries. The company expects to secure TRICARE provider status by August 31, 2025, accessing a program that disbursed $50.6 billion in medical treatments in FY2019.
Additionally, Adia Med anticipates approval as a United Healthcare provider by August 1, 2025, and has begun submitting its first patient insurance claims. The company offers regenerative treatments including Umbilical Cord Blood Stem Cell therapies, Autologous Hematopoietic Stem Cell Transplantation, and Therapeutic Plasma Exchange at its Winter Park clinic.
Adia Nutrition (OTCQB: ADIA) has partnered with CareCredit to offer patients financing options of up to $25,000 for medical treatments. This strategic move taps into the $48.35 billion U.S. healthcare finance solutions market as of 2023.
The company has transitioned from its previous provider, Cherry, to CareCredit as its primary financing partner. This partnership aims to make Adia's advanced treatments, including stem cell treatments and regenerative protocols, more accessible to patients through flexible payment options.
Adia Nutrition Inc. (OTCQB: ADIA) has announced the grand opening of its first licensed clinic, Adia Med of San Antonio, located in Texas. The clinic, led by Dr. Michele DeLeon, will offer FDA-registered regenerative medicine products including AdiaVita (containing 100 million viable cells and 3 trillion exosomes per unit) and AdiaLink (3.5 trillion exosomes per unit).
The new facility will collaborate with Adia Med of Winter Park on a clinical study investigating regenerative therapies for autism. The company is actively expanding its network through licensing opportunities, marking this opening as a strategic milestone in its growth plan.
Adia Nutrition Inc. (OTCQB: ADIA) is approaching a significant milestone as its medical subsidiary, Adia Med, nears final approval to become an in-network provider with United Healthcare. The anticipated approval, expected by August 1, 2025, will enable insurance coverage for Adia Med's advanced regenerative therapies including Autologous Hematopoietic Stem Cell Transplantation (AHSCT) and Therapeutic Plasma Exchange (TPE).
The company has already initiated its first patient insurance claim through United Healthcare, signaling progress toward integration. This strategic development will expand Adia Med's market reach by making its treatments accessible to United Healthcare's extensive patient network while establishing a scalable reimbursement pathway in the regenerative medicine sector.
Adia Nutrition Inc. (OTCQB: ADIA) has launched a nationwide TV commercial campaign for Adia Vita, its stem cell therapy product, using MNTN's (NYSE: MNTN) Connected TV platform. The product contains an impressive 100 million stem cells and 3 trillion exosomes per dose, positioning itself as a leader in the $15.1 billion global stem cell market.
The campaign aims to encourage patients to discuss Adia Vita with their physicians, highlighting the product's potential in regenerative medicine. The commercial emphasizes that physicians have the legal right to use approved biologic products like umbilical cord stem cells off-label when deemed appropriate for their patients.